Mark G Kris, MD Chief, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York
	Click here to download entire interview
Track 1	Cancer Care Ontario/ASCO guidelines for adjuvant chemotherapy and radiation therapy in Stage I to IIIA resectable non-small cell lung cancer (NSCLC)
Track 2	Clinical approach to treatment of Stage IB NSCLC
Track 3	Selecting adjuvant chemotherapy regimens for patients with NSCLC
Track 4	ECOG-E1505: Adjuvant cisplatin-based chemotherapy with or without bevacizumab in Stage IB to IIIA NSCLC
Track 5	Adjuvant radiation therapy for patients with resectable Stage IIIA NSCLC
Track 6	Utility of testing for K-ras mutations in patients with NSCLC
Track 7	Implications of EGFR mutations
Track 8	Managing the rash associated with EGFR inhibitors
Track 9	Testing for ERCC1 to predict benefit from cisplatin-based chemotherapy
Track 10	Updated staging system for lung cancer
Track 11	Clinical use of induction versus adjuvant therapy
Track 12	Clinical trials of preoperative gefitinib or bevacizumab
Track 13	NATCH: Surgery alone, induction therapy followed by surgery or surgery followed by adjuvant therapy
Track 14	Efficacy and toxicity of nanoparticle albumin-bound (nab) paclitaxel
Track 15	New developments in the understanding of EGFR mutations
Track 16	Combining erlotinib with bevacizumab
Track 17	Vandetanib (ZD6474): A dual VEGF and EGFR inhibitor
Track 18	Approach to the selection of second-line therapy
Track 19	Randomized trial of cisplatin with gemcitabine or pemetrexed as first-line therapy for NSCLC
Track 20	Trials evaluating cetuximab in lung cancer

Roman Perez-Soler, MD Chairman, Department of Oncology Montefiore Medical Center Gutman Professor of Medicine Albert Einstein College of Medicine Bronx, New York
	Click here to download entire interview
Track 1	AVAiL: Bevacizumab with cisplatin/gemcitabine for chemotherapy-naïve patients with advanced or recurrent nonsquamous NSCLC
Track 2	Toxicities associated with bevacizumab
Track 3	Clinical use of bevacizumab in patients with brain metastases
Track 4	FLEX: Cisplatin/vinorelbine with or without cetuximab as first-line therapy for NSCLC
Track 5	Role of pemetrexed/chemotherapy with or without bevacizumab in NSCLC
Track 6	Adjuvant chemotherapy doublets in ECOG-E1505
Track 7	Off-study dose of bevacizumab with carboplatin/paclitaxel as first-line therapy
Track 8	Combination therapy with bevacizumab/erlotinib in advanced NSCLC
Track 9	First-line therapy for nonsmokers or patients with EGFR mutations
Track 10	Use of maintenance bevacizumab after discontinuation of chemotherapy in advanced NSCLC
Track 11	Adjuvant therapy for patients with Stage IB NSCLC
Track 12	RADIANT: Erlotinib with or without adjuvant chemotherapy in Stage IB to IIIA, EGFR-positive NSCLC
Track 13	Tolerability and management of erlotinib-associated cutaneous toxicity
Track 14	Clinical trial evaluating vitamin K3 for the prevention of erlotinib-associated rash
Track 15	INTEREST: Equivalence of gefitinib and docetaxel as second-line therapy for advanced NSCLC
Track 16	Potential role of vandetanib in NSCLC
Track 17	Novel agents and targets in NSCLC
Track 18	EORTC trial of prophylactic cranial irradiation in extensive-disease small cell lung cancer after response to chemotherapy
Track 19	Summary of current developments in NSCLC

Julie R Brahmer, MD Assistant Professor of Oncology The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland
	Click here to download entire interview
Track 1	Predictors of response to EGFR tyrosine kinase inhibitors (TKIs)
Track 2	K-ras mutations and clinical decision-making in NSCLC
Track 3	Potential role for cetuximab in advanced NSCLC
Track 4	Clinical trials of vandetanib with chemotherapy in advanced NSCLC
Track 5	Evaluation of the anti-angiogenic agents sunitinib and sorafenib in advanced NSCLC
Track 6	ECOG-E4599: Carboplatin/paclitaxel with or without bevacizumab as first-line therapy
Track 7	Predictors of bevacizumab-associated hemoptysis
Track 8	ECOG-E4599: Outcomes for elderly patients treated with carboplatin and paclitaxel with bevacizumab
Track 9	Dose of bevacizumab in combination with chemotherapy for advanced NSCLC
Track 10	Use of bevacizumab in combination with chemotherapy or other biologic agents in later-line settings
Track 11	ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab in Stage IB to IIIA NSCLC
Track 12	Potential impact of bevacizumab on micrometastatic disease
Track 13	Use of neoadjuvant chemotherapy with or without radiation therapy in potentially resectable Stage III NSCLC

Philip Bonomi, MD Director, Division of Hematology/Oncology Alice Pirie Wirtz Professor of Medicine Rush University Medical Center Chicago, Illinois
	Click here to download entire interview
Track 1	Cisplatin/pemetrexed versus cisplatin/gemcitabine for chemotherapy-naïve patients with locally advanced or metastatic NSCLC
Track 2	Eligibility criteria in the selection of patients for treatment with bevacizumab
Track 3	Treatment algorithm for advanced NSCLC in nonsmokers with EGFR mutations
Track 4	Evolving clinical trial data with cetuximab in advanced NSCLC
Track 5	EGFR mutation status and clinical decision-making
Track 6	Ongoing clinical trial evaluating vandetanib in advanced NSCLC
Track 7	Clinical trials of chemoradiation therapy with biologic therapy for Stage III NSCLC
Track 8	ECOG adjuvant trial E1505: Chemotherapy with or without bevacizumab